Ovarian cancer screening

被引:65
作者
Urban, N
McIntosh, MW
Andersen, M
Karlan, BY
机构
[1] Fred Hutchinson Canc Res Ctr, Publ Hlth Serv, Canc Prevent Res Program, Seattle, WA 98109 USA
[2] Univ Washington, Dept Hlth Serv, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA
[3] Marsha Rivkin Ctr Ovarian Canc Res, Seattle, WA 98104 USA
[4] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[5] Cedars Sinai Med Ctr, Womens Canc Res Inst, Los Angeles, CA 90048 USA
[6] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Los Angeles, CA 90048 USA
[7] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90048 USA
关键词
D O I
10.1016/S0889-8588(03)00063-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In an ongoing effort to design an efficacious, cost-effective ovarian cancer screening method, the existing tests, CA 125 and transvaginal sonography, are being optimized and combined in a multimodal strategy, and new promising serum markers, such as mesothelin and HE4, are being developed and evaluated. Detection has been found to improve when multiple serum markers are used in a longitudinal logarithm. The parametric empirical Bayes approach improves screening algorithms by capturing the stability of markers over time in a heterogeneous population. It also has relatively simple extensions to multiple markers. The evaluation of markers increasingly accounts for characteristics of a woman that may affect her marker levels and accounts for the cancer's characteristics, histology, and grade. Receiver operating characteristic curves are helpful for evaluation because they relate a marker's sensitivity to the specificity at which it operates. Large, well-designed randomized controlled trials are under way to gauge the performance of existing screening methods.
引用
收藏
页码:989 / +
页数:18
相关论文
共 44 条
[1]  
*AM CANC SOC, 2002, AM CANC SOC CANC FAC
[2]   Worry about ovarian cancer risk and use of ovarian cancer screening by women at risk for ovarian cancer [J].
Andersen, MR ;
Peacock, S ;
Nelson, J ;
Wilson, S ;
McIntosh, M ;
Drescher, C ;
Urban, N .
GYNECOLOGIC ONCOLOGY, 2002, 85 (01) :3-8
[3]  
ANDERSEN MR, 2002, CLIN J WOMENS HLTH, V2, P5, DOI DOI 10.1053/CJWH.2002.31881
[4]   ELEVATION OF SERUM CA 125 PRIOR TO DIAGNOSIS OF AN EPITHELIAL OVARIAN-CARCINOMA [J].
BAST, RC ;
SIEGAL, FP ;
RUNOWICZ, C ;
KLUG, TL ;
ZURAWSKI, VR ;
SCHONHOLZ, D ;
COHEN, CJ ;
KNAPP, RC .
GYNECOLOGIC ONCOLOGY, 1985, 22 (01) :115-120
[5]   Tissue classification with gene expression profiles [J].
Ben-Dor, A ;
Bruhn, L ;
Friedman, N ;
Nachman, I ;
Schummer, M ;
Yakhini, Z .
JOURNAL OF COMPUTATIONAL BIOLOGY, 2000, 7 (3-4) :559-583
[6]  
Crump C, 2000, CANCER EPIDEM BIOMAR, V9, P1107
[7]   Transvaginal sonography as a screening method for the detection of early ovarian cancer [J].
DePriest, PD ;
Gallion, HH ;
Pavlik, EJ ;
Kryscio, RJ ;
vanNagell, JR .
GYNECOLOGIC ONCOLOGY, 1997, 65 (03) :408-414
[8]   Reported ovarian cancer screening among a population-based sample in Washington State [J].
Drescher, C ;
Holt, SK ;
Andersen, MR ;
Anderson, G ;
Urban, N .
OBSTETRICS AND GYNECOLOGY, 2000, 96 (01) :70-74
[9]   VARIABILITY IN RADIOLOGISTS INTERPRETATIONS OF MAMMOGRAMS [J].
ELMORE, JG ;
WELLS, CK ;
LEE, CH ;
HOWARD, DH ;
FEINSTEIN, AR .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1493-1499
[10]   PROJECTING INDIVIDUALIZED PROBABILITIES OF DEVELOPING BREAST-CANCER FOR WHITE FEMALES WHO ARE BEING EXAMINED ANNUALLY [J].
GAIL, MH ;
BRINTON, LA ;
BYAR, DP ;
CORLE, DK ;
GREEN, SB ;
SCHAIRER, C ;
MULVIHILL, JJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (24) :1879-1886